OPKO Health (NASDAQ:OPK) Stock Rating Reaffirmed by Piper Sandler

OPKO Health (NASDAQ:OPKGet Free Report)‘s stock had its “overweight” rating reiterated by investment analysts at Piper Sandler in a report issued on Monday, Benzinga reports. They presently have a $5.00 target price on the biotechnology company’s stock. Piper Sandler’s price target would suggest a potential upside of 270.37% from the company’s previous close.

A number of other equities analysts have also recently commented on OPK. Barrington Research dropped their target price on OPKO Health from $2.00 to $1.50 and set an “outperform” rating for the company in a report on Wednesday, February 28th. StockNews.com downgraded OPKO Health from a “hold” rating to a “sell” rating in a report on Friday, March 1st. Finally, HC Wainwright reiterated a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a report on Wednesday, February 28th.

Get Our Latest Report on OPK

OPKO Health Stock Up 3.1 %

NASDAQ OPK opened at $1.35 on Monday. The stock’s 50-day moving average price is $1.00 and its 200-day moving average price is $1.26. The company has a quick ratio of 1.22, a current ratio of 1.55 and a debt-to-equity ratio of 0.15. OPKO Health has a 52 week low of $0.85 and a 52 week high of $2.24. The company has a market capitalization of $940.94 million, a P/E ratio of -5.40 and a beta of 1.81.

OPKO Health (NASDAQ:OPKGet Free Report) last posted its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09). OPKO Health had a negative return on equity of 12.69% and a negative net margin of 21.76%. The firm had revenue of $181.90 million for the quarter, compared to the consensus estimate of $177.53 million. During the same quarter last year, the company earned ($0.11) earnings per share. The business’s revenue for the quarter was down 1.9% compared to the same quarter last year. On average, equities research analysts predict that OPKO Health will post -0.33 earnings per share for the current year.

Insider Buying and Selling

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 500,000 shares of the company’s stock in a transaction that occurred on Monday, March 18th. The shares were purchased at an average cost of $0.87 per share, for a total transaction of $435,000.00. Following the purchase, the chief executive officer now directly owns 210,968,225 shares in the company, valued at $183,542,355.75. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Phillip Md Et Al Frost purchased 500,000 shares of the company’s stock in a transaction on Monday, March 18th. The shares were acquired at an average price of $0.87 per share, for a total transaction of $435,000.00. Following the purchase, the chief executive officer now owns 210,968,225 shares in the company, valued at $183,542,355.75. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Richard M. Krasno purchased 30,000 shares of the company’s stock in a transaction on Monday, January 29th. The shares were purchased at an average price of $0.99 per share, for a total transaction of $29,700.00. Following the purchase, the director now owns 103,333 shares in the company, valued at approximately $102,299.67. The disclosure for this purchase can be found here. Insiders have acquired a total of 8,993,015 shares of company stock worth $8,479,069 in the last ninety days. 47.26% of the stock is owned by insiders.

Institutional Trading of OPKO Health

Large investors have recently added to or reduced their stakes in the company. State Street Corp lifted its holdings in shares of OPKO Health by 56.7% in the 1st quarter. State Street Corp now owns 27,688,831 shares of the biotechnology company’s stock valued at $95,250,000 after buying an additional 10,014,088 shares during the period. Millennium Management LLC lifted its holdings in shares of OPKO Health by 318.6% in the 2nd quarter. Millennium Management LLC now owns 7,390,435 shares of the biotechnology company’s stock valued at $18,698,000 after buying an additional 5,624,866 shares during the period. Invesco Ltd. lifted its holdings in shares of OPKO Health by 300.4% in the 3rd quarter. Invesco Ltd. now owns 5,164,180 shares of the biotechnology company’s stock valued at $8,263,000 after buying an additional 3,874,519 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of OPKO Health by 848.7% in the 2nd quarter. Renaissance Technologies LLC now owns 3,890,172 shares of the biotechnology company’s stock valued at $9,842,000 after buying an additional 3,480,129 shares during the period. Finally, Norges Bank acquired a new position in shares of OPKO Health in the 4th quarter valued at about $4,042,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

(Get Free Report)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.

Featured Stories

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.